Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
AAO: Corneal Toxicity Reported With Mirvetuximab Soravtansine
TUESDAY, Oct. 22, 2024 -- For patients receiving mirvetuximab soravtansine (MIRV) treatment for primary gynecologic malignancies, corneal toxicity is not...
AAO: Wastage Seen With Artificial Expiration of Eye Drops in Ophthalmic Clinics
TUESDAY, Oct. 22, 2024 -- Artificial expiration dates on eye drops in ophthalmology clinics result in significant waste in terms of medication, plastic, and...
FDA Approves Vyalev for Advanced Parkinson Disease
TUESDAY, Oct. 22, 2024 -- The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson...
Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly
Lund, Sweden — 22 October 2024 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete...
Removing Screen Time for One Hour Before Bed Aids Toddlers' Sleep
TUESDAY, Oct. 22, 2024 -- Parents can feasibly remove toddler screen time in the hour before bed and this removal is associated with improvements in toddler...
Computer-Aided Detection Colonoscopies Tied to Improved Adenoma Detection Rate
TUESDAY, Oct. 22, 2024 -- Compared with conventional colonoscopy, computer-aided detection (CADe) system-enhanced colonoscopies have an increased rate of...
Listeria Danger Spurs Nationwide Recall of Frozen Waffles
TUESDAY, Oct. 22, 2024 -- Treehouse Foods Inc. has recalled dozens of frozen waffle products because of potential listeria contamination. The recalled...
Washington Becomes 6th State to Report Bird Flu in Humans
TUESDAY, Oct. 22, 2024 (HealthDayNews) -- Four farm workers who helped cull poultry on an commercial egg farm in Washington are presumed to have been infected...
At-Home Brain Stimulation Treatment Can Safely Ease Depression
TUESDAY, Oct. 22, 2024 -- At-home brain stimulation therapy can safely and effectively treat severe to moderate depression, a new clinical trial shows. Rates...
Even Hardcore Smokers May Quit If Given Right Tools, Study Finds
TUESDAY, Oct. 22, 2024 -- Smokers find it easier to quit if they’re automatically offered support, even if they didn't ask for it, a new clinical trial...
Seniors Who Split: Rates of 'Gray Divorce' Have Tripled Since 1990
TUESDAY, Oct. 22, 2024 -- Baby Boom seniors are divorcing at rates triple that of a few decades ago, a new study has found. “Gray divorce” among...
FDA Approves Vyloy (zolbetuximab-clzb) for the Treatment of Advanced Gastric and GEJ Cancer
TOKYO, Oct. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug...
FDA Approves Vyalev (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
NORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyalev...
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)
CHATHAM, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced the submission of a...
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of Bimzelx (bimekizumab-bkzx)
Brussels (Belgium), October 14, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug...
FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara
RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of...
Stealth BioTherapeutics Announces Positive Vote from FDA Advisory Committee Meeting Supporting Potential Approval of Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., Oct. 11, 2024 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage...
FDA Approves Hympavzi (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE) October 11, 2024 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Hympavzi...
U.S. Food and Drug Administration (FDA) Accepts New Drug Application for Elinzanetant
Berlin, October 9, 2024 – Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application...
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 3, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
AACHEN, Germany, Oct. 22, 2024 . Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for...
Darling Ingredients Announces Publication of Peer-Reviewed Collagen Peptides Study and its Impact on Post-Meal Blood Glucose Spikes
IRVING, Texas, Oct. 21, 2024. Darling Ingredients Inc. today announced the publication of preclinical and clinical studies1 in the Wiley Journal of Food...
Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast cancer
SAN DIEGO, Oct. 18, 2024. MeCo Diagnostics, a venture-backed startup dedicated to unlocking a new therapeutic modality for cancer, has announced a publication...
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE) October 19, 2024 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside...
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
RAHWAY, N.J., Oct. 17, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.